Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
4.950
-1.210 (-19.64%)
At close: Apr 1, 2025, 4:00 PM
6.67
+1.72 (34.69%)
After-hours: Apr 1, 2025, 5:02 PM EDT

Elicio Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
11.3311.95.637.543
Upgrade
Research & Development
33.6623.8518.117.9312.72
Upgrade
Operating Expenses
44.9935.7523.7325.4715.72
Upgrade
Operating Income
-44.99-35.75-23.73-25.47-15.72
Upgrade
Interest Expense
--1.06-3.6-0.88-
Upgrade
Interest & Investment Income
-0.370.0700.01
Upgrade
Currency Exchange Gain (Loss)
-0.2---
Upgrade
Other Non Operating Income (Expenses)
-6.910.43-0.95-0.05-
Upgrade
EBT Excluding Unusual Items
-51.9-35.8-28.21-26.4-15.71
Upgrade
Other Unusual Items
-0.610--
Upgrade
Pretax Income
-51.9-35.2-28.21-26.4-15.71
Upgrade
Net Income
-51.9-35.2-28.21-26.4-15.71
Upgrade
Net Income to Common
-51.9-35.2-28.21-26.4-15.71
Upgrade
Shares Outstanding (Basic)
12501511
Upgrade
Shares Outstanding (Diluted)
12501511
Upgrade
Shares Change (YoY)
141.35%1500.08%-97.93%42.39%172.21%
Upgrade
EPS (Basic)
-4.25-6.96-89.27-1.73-1.46
Upgrade
EPS (Diluted)
-4.25-6.96-89.27-1.73-1.46
Upgrade
Free Cash Flow
--32.76-22.83-24.46-16.9
Upgrade
Free Cash Flow Per Share
--6.48-72.26-1.60-1.57
Upgrade
EBITDA
-44.67-35.36-23.34-25.22-15.53
Upgrade
D&A For EBITDA
0.310.380.390.250.19
Upgrade
EBIT
-44.99-35.75-23.73-25.47-15.72
Upgrade
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q